CooperSurgical

CooperSurgical

CooperSurgical operates as a specialized medical device and technology company focused exclusively on women's health and fertility. For nearly three decades, the firm has pursued a disciplined acquisition strategy, integrating a family of brands that span the full reproductive care continuum. Its portfolio covers contraception, fertility, general gynecological surgery, and birth. The company maintains operational hubs in Mountain View, Manchester, Budapest, Jackson, and Boston, reflecting a manufacturing and regulatory presence shaped by FDA 21 CFR and ISO 13485 standards. The firm's product strategy combines in-house engineering with targeted acquisitions. Its hardware lines include time-lapse incubators and micromanipulation systems for IVF labs. Consumables range from culture media to embryo-transfer catheters. A recently added molecular diagnostics layer — exemplified by the ZyMōt Fertility acquisition, a subsidiary of DxNow, Inc. — brings microfluidic sperm-separation devices under its umbrella. This device-centric model means CooperSurgical competes less with health systems and more with other specialized medtech consolidators. Its go-to-market relies on direct sales to fertility clinics, hospitals, and OB/GYN practices across North America and Europe. Financial metrics for the privately structured entity are not publicly disclosed. Headcount spans at least the five named office locations, with active recruitment for roles in quality control, plant management, and clinical lab technology. No dedicated venture arm, philanthropic foundation, or external co-investor club is visible in public records. In recent months, CooperSurgical completed the acquisition of ZyMōt Fertility (announced via the firm's website), folding the microfluidics company into its existing reproductive health portfolio to strengthen its consumables offering for andrology labs. CooperSurgical's structural differentiator is its role as an operating company, not a fund. Unlike family offices or asset managers that deploy capital into third-party firms, CooperSurgical acquires and integrates operating subsidiaries with direct manufacturing and regulatory oversight. This architecture creates a single consolidated compliance surface — FDA registration, batch-level certification, and ISO-certified quality systems — that functions as both a barrier to entry and a recurring-revenue moat tied to clinic supply contracts.